CRDF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	2.14M
Gjennomsnittsvolum	1.91M
Markedsverdi	157.38M
EPS	$0 ( 2024-05-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.78
ATR14	$0.0660 (1.88%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-07	Levine James E.	Buy	205 008	Stock Options
2024-03-07	Kabbinavar Fairooz	Buy	205 008	Stock Options
2024-03-07	Smeal Tod	Buy	205 008	Stock Options
2024-03-07	Erlander Mark	Buy	510 000	Stock Options
2023-12-19	Pace Gary W	Buy	30 000	Common Stock

INSIDER POWER
82.09
Last 96 transactions
Buy: 6 518 913 \| Sell: 700 088

Volum Korrelasjon

Lang: -0.47 (neutral)

Kort: -0.33 (neutral)

Signal:(40.926) Neutral

Cardiff Oncology Inc Korrelasjon

10 Mest positive korrelasjoner
EBAY	0.964
CPRT	0.963
XLRN	0.96
MSTR	0.96
DAX	0.958
DWAC	0.956
GRMN	0.955
CRAI	0.953
FDT	0.953
BWMX	0.952

10 Mest negative korrelasjoner
VORB	-0.942
TWKS	-0.938
PEAR	-0.934
SMSI	-0.934
TEDU	-0.923
UONE	-0.919
TTEC	-0.918
QNRX	-0.915
BRQS	-0.915
BMBL	-0.914

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Cardiff Oncology Inc Korrelasjon - Valuta/Råvare

0.26
( neutral )

0.03
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.60
( weak negative )

-0.02
( neutral )

Cardiff Oncology Inc Økonomi

Annual	2023
Omsetning:	$488 000
Bruttogevinst:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2023
Omsetning:	$488 000
Bruttogevinst:	$90 000.00 (18.44 %)
EPS:	$-0.930

FY	2022
Omsetning:	$386 000
Bruttogevinst:	$186 000 (48.19 %)
EPS:	$-0.860

FY	2021
Omsetning:	$359 000
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.